* Note: Prices are in Million (M) USD.
Description:
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $94 M
Debt : $415 M
EBITDA : $290 M
Net Debt (Debt - Cash): $321 M
Since Net Debt is covered by EBITDA within 2 years, 2 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Medical instruments & supplies
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 44.94
Since Forward PE Ratio is greater than 35, 0 point assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 6 overlapping fiscal years (max 20).Average Free Cash Flow: $-98 M
Average Revenue: $869 M
Revenue Converted To Free Cash Flow (%): -11.2%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $1,104 M
Revenue 4 Years Ago (2020-12-31): $662 M
Last 5 Years Average Revenue Growth: 13%
Since Revenue Growth is between 10 - 15, 3 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $273 M
Share Count 5 Years Ago (2020-12-31): $265 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.63
Trailing 12-Month Earnings Per Share (EPS): $0.52
Average Earnings Per Share (EPS): $0.58
Dividend Per Share (DPS): $0
Payout Ratio: 9%
Dividend Yield: 0%
Since company Payout Ratio is less than 50, 2 points assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 6 valid ROE years (max 20).Average ROE: 15.3%
Since Average ROE is between 10 - 20, 3 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $26
52-Week Low: $17
Threshold Price (15% Above 52-Week Low): $20
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $7,248 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 14 points to above Stevanato Group SpA (STVN) stock.
Heads up: One or more P/E inputs look exaggerated and may skew the blend.
• Last 4 Years Avg PE
38.72 (>2× median)
Further research is recommended; please use your own due diligence.In such cases, multiplying earnings by the long-run average P/E typically gives a closer, more reliable fair value.
Rule of thumb: Last 4 Years Avg P/E (38.72)
× EPS ($0.58) = $22.26.
Last 4 Years Avg PE
38.72, Fair Value PE
12, Industry Based PE
18, Growth Based PE
13.35, ROE Based PE
15.27, Risk-Free Anchored PE (25% MoS)
17.61. Based on these 6 values, average assigned is
19.16. Value-Trades has assined P/E value
19.17. An average (Current Year EPS + Next Year EPS) earning per share is
$0.575.
Note: Final fair value is the lesser of the blended PE-based fair value and the simple average PE × EPS fair value.Fair value using multiple P/Es (blended): $11.02 (PE 19.16 × EPS $0.58)
Fair value using simple average PE × EPS: $22.26 (PE 38.72 × EPS $0.58)
Lesser of these two: $11.02
So the Final Fair Value is: $11.02
